Our research group is mainly devoted to understanding why immune responses are insufficient to clear HBV, HCV and HEV in chronic patients, and if anti-viral therapy can revert this. Besides this, a major effort focusses on the search for new biomarkers to predict the development of hepatobiliary cancers in patients at risk.

The research, conducted by both biologists and medical doctors combines basic immunological studies in mice with translational studies using patient cohorts. In this, various longitudinal studies focused on improvement of therapy, and participation in a number of multi-center Phase I/II clinical trials are being performed.